Dishman Carbogen Amcis - India CRAMS’ Normalisation Expected Q1 FY22 Onwards: Nirmal Bang
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Nirmal Bang Report
Dishman Carbogen Amcis Ltd.’s Q3 FY21 revenue at Rs 4,632 million was up 5% QoQ. India revenue continued to be weak.
Overall contract research and manufacturing services revenue was down 3% QoQ while marketable molecule revenue was up 35% QoQ. India CRAMS revenue stood at Rs 200 million, down 61% YoY.
Marketable molecule business benefited from the supply of disinfectants.
Ebitda at Rs 630 million was down by 22% QoQ. Ebitda was adversely impacted by higher other expenses, which were up 40% QoQ, which included a forex loss of Rs 214 million.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.